Simply Wall St
4 min read
As global markets navigate a complex landscape of economic indicators and geopolitical tensions, Asian stock markets present intriguing opportunities for investors seeking value. In this context, identifying stocks that are priced below their estimated worth can be particularly appealing, as these undervalued equities may offer potential for growth amidst the broader market fluctuations.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Shenzhen KSTAR Science and Technology (SZSE:002518) |
CN¥22.30 |
CN¥43.65 |
48.9% |
|
PixArt Imaging (TPEX:3227) |
NT$220.00 |
NT$436.06 |
49.5% |
|
Livero (TSE:9245) |
¥1716.00 |
¥3347.40 |
48.7% |
|
Kanto Denka Kogyo (TSE:4047) |
¥862.00 |
¥1687.52 |
48.9% |
|
J&T Global Express (SEHK:1519) |
HK$6.79 |
HK$13.27 |
48.8% |
|
Good Will Instrument (TWSE:2423) |
NT$44.50 |
NT$87.18 |
49% |
|
Ficont Industry (Beijing) (SHSE:605305) |
CN¥26.82 |
CN¥52.35 |
48.8% |
|
Everest Medicines (SEHK:1952) |
HK$54.70 |
HK$106.95 |
48.9% |
|
Brangista (TSE:6176) |
¥604.00 |
¥1178.82 |
48.8% |
|
APAC Realty (SGX:CLN) |
SGD0.46 |
SGD0.90 |
49.1% |
Below we spotlight a couple of our favorites from our exclusive screener.
Overview: Kolmar Korea Co., Ltd. is engaged in the research, development, production, and sale of beauty and health products both domestically and internationally, with a market cap of ₩2.17 trillion.
Operations: Kolmar Korea Co., Ltd. generates revenue primarily from cosmetics (₩1.33 trillion), medicines (₩838.45 billion), packaging (₩272.41 billion), and food products (₩87.76 billion).
Estimated Discount To Fair Value: 44.8%
Kolmar Korea is trading at ₩92,100, significantly below its estimated fair value of ₩166,823.52. Despite a high debt level and large one-off items affecting results, the company’s earnings grew by a very large amount over the past year and are forecast to grow 22.07% annually over the next three years, outpacing both revenue growth of 9.8% and market averages. Recent investor calls aim to clarify business status amid these financial dynamics.
-
The growth report we’ve compiled suggests that Kolmar Korea’s future prospects could be on the up.
-
Dive into the specifics of Kolmar Korea here with our thorough financial health report.
Overview: Cosmax, Inc. is engaged in the research, development, production, and manufacturing of cosmetic and health functional food products both in Korea and internationally, with a market cap of ₩2.72 trillion.
Operations: The company’s revenue is primarily derived from the Cosmetics Sector, which accounts for ₩2.23 trillion.
